Erasca (NASDAQ:ERAS) Trading 8.2% Higher – Here’s What Happened

Posted by George Bondi on May 20th, 2026

Erasca, Inc. (NASDAQ:ERAS – Get Free Report) shares traded up 8.2% during mid-day trading on Wednesday . The stock traded as high as $11.01 and last traded at $11.1650. 806,783 shares were traded during trading, a decline of 88% from the average session volume of 6,930,173 shares. The stock had previously closed at $10.32.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price objective on Erasca from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 18th. Mizuho cut their target price on Erasca from $28.00 to $26.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 12th. Piper Sandler raised their target price on Erasca from $11.00 to $18.00 and gave the company an “overweight” rating in a research note on Friday, March 13th. Citigroup reiterated a “buy” rating on shares of Erasca in a research note on Friday, March 13th. Finally, Guggenheim raised their target price on Erasca from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, March 16th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.75.

Get Our Latest Analysis on ERAS

Erasca Price Performance

The company has a market capitalization of $3.48 billion, a price-to-earnings ratio of -12.05 and a beta of 0.68. The business has a fifty day moving average price of $15.03 and a 200 day moving average price of $9.74.

Erasca (NASDAQ:ERAS – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). Research analysts anticipate that Erasca, Inc. will post -0.55 earnings per share for the current year.

Insider Transactions at Erasca

In related news, insider Shannon Morris sold 20,000 shares of Erasca stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $15.04, for a total value of $300,800.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Ebun Garner sold 80,000 shares of Erasca stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $16.40, for a total value of $1,312,000.00. Following the completion of the transaction, the insider directly owned 25,076 shares in the company, valued at $411,246.40. This represents a 76.14% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 14.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Erasca

Institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its stake in Erasca by 58.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 21,579 shares of the company’s stock valued at $27,000 after acquiring an additional 7,923 shares in the last quarter. EP Wealth Advisors LLC purchased a new position in Erasca during the 2nd quarter valued at about $29,000. Russell Investments Group Ltd. purchased a new position in Erasca during the 3rd quarter valued at about $31,000. SG Americas Securities LLC purchased a new position in Erasca during the 3rd quarter valued at about $32,000. Finally, EntryPoint Capital LLC purchased a new position in Erasca during the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 67.78% of the company’s stock.

About Erasca

(Get Free Report)

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.